AstraZeneca AZN announced today that it has notified Abbott that it will discontinue the development of CERTRIAD, which was being investigated for the treatment of mixed dyslipidemia. This means the co-development and license agreement with Abbott will end on January 22, 2011.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
